QHSLab Inc · OTC:USAQ
QHSLab — Investor Presentation (May 2025)
29 slides from QHSLab's investor presentation, May 21, 2025
Slide 1: Empowering Healthcare Through Digital Medicine
G GHSLAB Empowering Healthcare Through Digital Medicine Innovation Revolutionizing Primary Care: New Vision. New Opportunities. QHSLab.com Stock Symbol: USAQ Corporate Presentation - May 2025
Slide 2: Forward-Looking Statements & Disclaimers
CG QHSLAB Forward-Looking Statements & Disclaimers This presentation contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this presentati
Slide 3: Key Takeaways for Investment
G QHSLAB Key Takeaways for Investment Revenue Producing: QHSLab's business model generates recurring revenue for the company itself and its medical practitioner clients. This revenue comes from a large and continuously expanding addressable end market. Positioned for Growth: We are favorably aligned
Slide 4: Financial Turnaround: Narrowing Net Loss with Strong Revenue Growth
Cy QHSLAB Financial Turnaround: Narrowing Net Loss with Strong Revenue Growth and Significant Increases in Gross Profit Annual Performance Most Recent Quarter $2.1 0.6 i <> A < ak 0.3 | | 7 Revenue Gross profit Revenue Gross profit 2023 m2024 mQ1 2024 mQi1 2025 Building on a record-breaking year of
Slide 5: Path to Profitability
CG QHSLAB Path to Profitability Revenue Growth: + $2.1M for 2024, up 51% year-over-year. * $645,000 for Q1 2025, up 32% year-over-year * Growth reflects increasing adoption of our solutions and a strong market presence. Profitability Milestones: + After years of investment, QHSLab is approaching pro
Slide 6: Highly-Profitable Business Model
CG QHSLAB Highly-Profitable Business Model Our scalable and straightforward business model enables providers to deliver better care while generating additional revenue. Here’s how our key revenue streams break down: Allergy Diagnostic Kits: $100 per test — $12,000 annually per provider Immunotherapy
Slide 7: Leveraging Our Strengths & Competitive Advantages
CG QHSLAB Leveraging Our Strengths & Competitive Advantages Aan ee Product Profile: Exclusive product line featuring FDA-cleared diagnostic equipment, widely accepted by Medicare and private insurance providers. Advanced Technology Platform: The QHSLab Expert System efficiently processes large volum
Slide 8: Vision and Execution: Transforming Primary Care
CG QHSLAB Vision and Execution: Transforming Primary Care Our Dedication: To revolutionize patient care through well-integrated programs not only sets new industry standards but also positively impacts the overall well-being of patients. Our Mission: To improve the quality of life for individuals an
Slide 9: The Problem: Primary care gaps are failing millions of patients
CG QHSLAB The Problem: Primary care gaps are failing millions of patients, driving untreated conditions and worsening outcomes. Doctor Lack Time and Tools: 18 minutes* per patient visit —too short for comprehensive care. 40%** of mental health issues and 50% of allergy symptoms go undiagnosed. (*sou
Slide 10: The True Cost of Gaps in Primary Care
Cy QHSLAB The True Cost of Gaps in Primary Care: Too Many Patients, Too Little Time leading to Overwhelmed Providers, Underserved Patients. Untreated Conditions Escalate: Millions of undiagnosed and poorly managed conditions lead to preventable complications and chronic illnesses. Quality of Care Fa
Slide 11: Intelligent Tools & Patient-Centric Health Care Technologies
G QHSLAB Intelligent Tools & Patient-Centric Health Care Technologies for Smarter Primary Care Advanced Patient Engagement: Interactive digital tools collect meaningful data from patients, uncovering hidden symptoms. Data-Driven Insights: Robust back-end organizes patient input into actionable insig
Slide 12: Transforming Patient Data into Clinical Insights and Better Health Outcomes
G QHSLAB Transforming Patient Data into Clinical Insights and Better Health Outcomes ASSESSMENT Health Questionnaire ee ~ ASSESSMENT IN PROGRESS Allergy Baseline Assessment —_—_—_—_————— Our Mission: Improving quality of life through physician-directed digital health and innovative point-of- care so
Slide 13: Empowering Providers and Patients with Intelligent, Reimbursable Solutions
10:59 @ GHSLAB Recommended For You Mastering Back Pain Part 1 video Library Eatwell Diabetes , on the GETITON @ App Store Google Play Cy QHSLAB Empowering Providers and Patients with Intelligent, Reimbursable Solutions What It Does: A cloud-based software that engages patients, uncovers hidden condi
Slide 14: Integrating Mental Health & Allergic Disease Management
CG QHSLAB Integrating Mental Health & Allergic Disease Management The Connection: Allergies significantly impact mental health, work productivity, and overall well- being. Patients with allergies are more likely to experience depression and anxiety. Key Insights: Hay fever sufferers have a 1.6x high
Slide 15: Q-Scale: Mental Health Insights for Better Care
Gy QHSLAB Q-Scale: Mental Health Insights for Better Care What It Does: The Q-Scale measures patients’ quality of life across sleep, stress, anxiety, pain, and overall life satisfaction. Identifies high-risk mental health concerns for early intervention. How It Works: Estimated Time to Complete 12mi
Slide 16: The Demand for Mental Healthcare Grows
CG QHSLAB The Demand for Mental Healthcare Grows assesment devas om Adults with medical illnesses are more likely to experience depression, and those with depression face a higher risk of chronic diseases. Chronic conditions affect 6 in 10 Americans, driving $4.1 trillion Your Health Habit Scores in
Slide 17: Allergy: Key Products, Features and Proven Impact
CG QHSLAB Allergy: Key Products, Features and Proven Impact Proven Impact: Serves a massive market: Over 150M Americans suffer from allergies, costing $16B annually in OTC and prescription treatments, by simplifying allergy care, QHSLab enables primary care providers to treat their patients, making
Slide 18: Addressing Allergies and Mental Health
G QHSLAB Addressing Allergies and Mental Health Enhanced Patient Care: Integrating allergy testing and treatment with mental health programs in primary care enables comprehensive patient care, improving outcomes and well-being by 1 addressing physical and mental health needs. Streamlined Workflow: I
Slide 19: Market Opportunity and Growth Potential
G QHSLAB Market Opportunity and Growth Potential TAM (Total Addressable Market) Mental Health Market: $109B in 2023, projected to reach $167B by 2032. + Allergy Testing Market: Rapid growth driven by increasing demand for in-office diagnostic solutions. SAM (Serviceable Available Market) Primary Car
Slide 20: Competitive Landscape: QHSLab's Unique Position
CG QHSLAB Competitive Landscape: QHSLab's Unique Position in Mental Health and Allergy Solutions Mental Health Assessments: 1. Competitors: Online tools like Kaiser Permanente’s Mental Health Care Hub, and standalone platforms such as BetterHelp and Talkspace. 2. Challenges for Competitors: 1.Lack o
Slide 21: QHSLab's Unique Differentiators
G QHSLAB f a a QHSLab’s: Unique Differentiators J Comprehensive Suite: Combines mental health and allergy solutions in one platform, streamlining care for primary practices. Reimbursable Tools: Services align with CPT codes, ensuring seamless insurance reimbursement. Accessibility: Makes high-qualit
Slide 22: Addressing Challenges: Building a Stronger Future
Gy QHSLAB Addressing Challenges: Building a Stronger Future Acknowledging the Past Growth has been slower due to a deliberate focus on achieving product-market fit and navigating financial constraints, including managing convertible debt. Current Readiness QHSLab’s products are now clinically valida
Slide 23: Path Forward: Unlocking Growth with Strategic Investment
Gy QHSLAB Path Forward: Unlocking Growth with Strategic Investment With a clear foundation in place, new investments will directly accelerate QHSLab's growth by addressing key priorities: Eliminate Convertible Debt: Free up cash flow to invest in scaling operations and expanding our reach. Expand Sa
Slide 24: Benefits to Doctors That Drive QHSLab's Revenue
Cy QHSLAB Benefits to Doctors That Drive QHSLab's Revenue Annual Revenue ($M) 50 150 Number of Physicians 300 Empowering Physicians, Driving Revenue Nearly 50% of primary care physicians (~250,000) are independent, handling over 52% of all physician office visits. Innovative Solutions QHSLab’s solut
Slide 25: Positioned for Growth In a Changing Healthcare Landscape
Gy QHSLAB Positioned for Growth In a Changing Healthcare Landscape Allergy Care Gap: 60 million Americans suffer from allergic disorders, with fewer than 3,000 practicing allergists. Demand for allergy services is expected to rise by 35%, while the number of allergists is declining. Telemedicine Ado
Slide 26: Operational Excellence that Driving Growth and Visibility
CG QHSLAB Operational Excellence that Driving Growth and Visibility See All Health Questionnaire Completed on 01/10/21, view General Fitness & Wellness. Completed on 12/29/20 o Ss Poocasts viveos ARTICLES 2New New Sathenahealth Expanding Recurring Revenue: Growing adoption of point-of-care and digit
Slide 27: Expanding Our Presence and Thought Leadership
Cy QHSLAB Expanding Our Presence and Thought Leadership Allergy Diagnostics & Allergen Immunotherapy Workshop QHS LIVE VIRTUAL CONFERENCE Sat 6, 2021 “Mens Sana in Corpore Sano”: How the QHSLab Digital Medicine Tools on The Bidirectional Relationship Between ‘Transformed This Doctor's Practice Menta
Slide 28: Executive Leadership Team
y QHSLAB Executive Leadership Team TROY GROGAN, PRESIDENT AND CEO He brings a wealth of expertise as a medical device manufacturer _ and the founder of a successful workplace wellness company. He was formerly appointed by the Minister of Health to oversee one of Australia's largest health systems in
Slide 29: ¥ QHSLAB
¥ QHSLAB General Inquiries hello@ghslab.com Investor Relations ir@usaqcorp.com QHSLab, Inc. 901 Northpoint Parkway Suite 302, West Palm Beach, FL 33407 www.usaqcorp.com Corporate Presentation - May 2025